Compounds > gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate
Page last updated: 2024-09-03

gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate and Acute Kidney Failure

gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate has been researched along with Acute Kidney Failure in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Alison, D; Bacigalupo, L; Billiouw, JM; Boffa, JJ; Campioni, P; Deray, G; Devos, D; Ferreiros, J; Glowacki, F; Hannedouche, T; Maes, B; Marti-Bonmati, L; Rigothier, C; Rouviere, O; Vrtovsnik, F1
Beaufils, H; Bourbouze, R; Brillet, G; Deray, G; Dubois, M1

Trials

1 trial(s) available for gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate and Acute Kidney Failure

ArticleYear
Safety of meglumine gadoterate (Gd-DOTA)-enhanced MRI compared to unenhanced MRI in patients with chronic kidney disease (RESCUE study).
    European radiology, 2013, Volume: 23, Issue:5

    Topics: Acute Kidney Injury; Aged; Contrast Media; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Heterocyclic Compounds; Humans; Magnetic Resonance Imaging; Male; Nephrogenic Fibrosing Dermopathy; Organometallic Compounds; Prevalence; Renal Insufficiency, Chronic; Risk Factors; Treatment Outcome

2013

Other Studies

1 other study(ies) available for gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate and Acute Kidney Failure

ArticleYear
Renal tolerance of gadolinium-DOTA and gadolinium-DTPA in rats.
    Investigative radiology, 1994, Volume: 29, Issue:3

    Topics: Acute Kidney Injury; Animals; Contrast Media; Diatrizoate; Gadolinium DTPA; Heterocyclic Compounds; Kidney; Magnetic Resonance Imaging; Male; Organometallic Compounds; Pentetic Acid; Rats; Rats, Sprague-Dawley

1994